Reference
Dalal RS, et al. Cytomegalovirus colitis is rarely observed after initiation of infliximab, adalimumab, or vedolizumab in biologic-naive patients with ulcerative colitis. American Journal of Gastroenterology 116 (Suppl.): S334-S335 abstr. S731, Oct 2021. Available from: URL: http://doi.org/10.14309/01.ajg.0000776456.24856.73 [abstract]
Rights and permissions
About this article
Cite this article
Adalimumab/infliximab. Reactions Weekly 1885, 29 (2021). https://doi.org/10.1007/s40278-021-06788-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-06788-8